ALS Phase II Study of NX210c

Summary

This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).

Timeline

Start

2024-10-25

Primary completion

2026-02-01

Completion

2026-09-30

Outcome

Missed primary endpoint

release “While NX210c did not meet the primary endpoint of change from baseline to week-6 in NfL or albumin quotient between cerebrospinal fluid and blood (Qalb)” axoltis.com ↗

Drugs

Indications